BMY Zenbexus: First CELMoD Approval in Myeloma

The FDA granted accelerated approval on August 13 to Bristol Myers Squibb’s (BMY) Zenbexus (iberdomide), the first CELMoD (cereblon E3 ligase modulator) to reach the market. Zenbexus is approved in combination with daratumumab, hyaluronidase-fihj, and dexamethasone, a triplet BMS calls ZDd, for adults with relapsed or refractory multiple myeloma who have had at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The decision landed four days ahead of the August 17 PDUFA date.

The approval rests on EXCALIBER-RRMM, which randomized 939 patients overall. The MRD analysis covered the first 420 randomized to ZDd (n=207) or daratumumab, bortezomib, and dexamethasone (DVd, n=213). At a median follow-up of 16 months, ZDd produced a minimal residual disease (MRD)-negative complete response in 41% of patients versus 21% for DVd (p<0.0001). MRD negativity means no detectable cancer cells at the most sensitive level of testing, the strictest measure of response in myeloma. This is the first myeloma approval based on MRD-negative complete response rather than progression-free survival.

The mechanism is why this matters beyond one drug. Revlimid and Pomalyst, BMS’s older immunomodulatory drugs, bind cereblon but degrade it imprecisely. CELMoDs like iberdomide are engineered to degrade disease-driving proteins more potently, and BMS is positioning the class as the successor to a franchise that has anchored its oncology business for a decade. Multiple myeloma accounts for roughly 35,000 new US diagnoses a year, and nearly every patient eventually relapses, so each new line of therapy matters. A second CELMoD, mezigdomide, is under FDA review with a May 13, 2027 PDUFA date, as covered in the mezigdomide PDUFA analysis.

The boxed warnings are not cosmetic. Neutropenia hit 90.2% of patients on ZDd and infections 78.9%, with warnings for embryo-fetal toxicity and venous and arterial thromboembolism. Fatal adverse reactions occurred in 4.9% of patients. Because this is an accelerated approval, BMS must confirm clinical benefit in follow-up trials, with the progression-free survival endpoint still outstanding.

BMS shares closed at $65.47 on August 20. The company is fighting the Eliquis and Opdivo patent cliff, and its rumored $400 billion AstraZeneca tie-up was reported denied. A de-risked next-generation oncology franchise is the counterweight to that standalone thesis. For the broader competitive picture in myeloma, see the CAR-T versus bispecifics breakdown.

What to watch next: full EXCALIBER-RRMM data expected this year, including whether the MRD benefit translates into a progression-free survival win that converts this accelerated approval into full approval.

What It Means for the Trade

The approval’s significance is structural: this is the first myeloma accelerated approval based on MRD-negative complete response rather than PFS, and that regulatory precedent matters beyond BMY. MRD negativity is the field’s most sensitive measure of disease eradication — 41% versus 21% against a daratumumab-based comparator at 16 months’ follow-up (p<0.0001) — and the FDA accepting it as the basis for an oncology approval signals a pathway every myeloma sponsor will now study. For BMY specifically, the first-CELMoD-to-market position opens the successor chapter to the Revlimid/Pomalyst franchise that anchored its oncology revenue for a decade, at precisely the moment those older immunomodulators face generic erosion. Mezigdomide behind it with a May 2027 PDUFA gives the class two shots at the same succession.

The four-days-early approval and the ZDd triplet structure tell you the commercial positioning: iberdomide paired with daratumumab plus dexamethasone slots into the post-proteasome-inhibitor relapse setting where daratumumab-based regimens are already the backbone — the launch is a substitution play into existing prescribing patterns, not a paradigm-change sell. That is the easiest commercialization path a new myeloma drug can have, and the accelerated status means revenue starts now while the confirmatory PFS data matures.

Mechanism and Franchise Context

The CELMoD engineering is the whole competitive claim. Older cereblon modulators (lenalidomide, pomalidomide) bind cereblon but degrade disease-driving substrates — ikaros and aidos transcription factors — inefficiently and with broad immunomodulatory baggage. Iberdomide is engineered for higher cereblon affinity and more potent substrate degradation, which is the mechanistic basis for expecting deeper responses at better tolerability. The clinical translation in EXCALIBER-RRMM: a doubling of MRD-negative complete responses. The unanswered question is durability — MRD negativity is a surrogate, the approval is accelerated, and the PFS endpoint is still outstanding. The confirmatory data expected this year is where the class either becomes the new backbone or an expensive response-rate improvement.

The safety profile is the label’s practical constraint: neutropenia at 90.2% and infections at 78.9% with a 4.9% fatal adverse reaction rate are the classic myeloma triplet profile, heavy as expected, and the boxed warnings (embryo-fetal toxicity, thromboembolism) mirror the Revlimid label’s decades-old risk management infrastructure — a familiar REMS apparatus that actually eases launch logistics for prescribers already trained on it.

Risks and What Could Go Wrong

1. The confirmatory PFS readout disappoints: the entire accelerated approval rests on a surrogate, and a PFS miss triggers the standard conversion problem — withdrawal risk or a relabeled, commercially diminished product.
2. Mezigdomide’s May 2027 PDUFA: a second CELMoD approval is franchise depth, but a mezigdomide surprise (positive or negative) re-prices the whole class story in one event.
3. The myeloma sequencing fight: BCMA-directed therapies are capturing the relapsed landscape earlier, and CELMoDs must win their position in combination sequences against cell-therapy and bispecific momentum.
4. Company-level noise: BMY is fighting the Eliquis and Opdivo patent cliffs, and after the reported AZN merger denial, the standalone-thesis quality depends on exactly these de-risked franchise successions executing.

Position read: this is the franchise-succession event BMY’s standalone case needed — first-mover in a new class with a second asset behind it. Hold the core through the confirmatory PFS data; that readout, not the launch quarter, is the next valuation checkpoint.

Source: EXCALIBER-RRMM on ClinicalTrials.gov (NCT04975997); BMS Phase 3 EXCALIBER-RRMM announcement